Literature DB >> 20363134

Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ).

Mieke C E Hermans1, Catharina G Faber, Marc H De Baets, Christine E M de Die-Smulders, Ingemar S J Merkies.   

Abstract

We describe the development of an outcome measure of activity and participation for patients with myotonic dystrophy type 1 using the Rasch measurement model. A 49-item questionnaire was completed by 163 DM1 patients. Data were subsequently analyzed with Rasch software to design the item set to fit model expectations. Through systematic investigation of response category ordering, model fit, item bias, and local response dependency, we succeeded in constructing a 20-item unidimensional scale of activity and participation (DM1-Activ). High internal consistency (PSI=0.95) and good test-retest reliability values of item difficulty hierarchy and patient location were demonstrated. Patient measures had acceptable correlations with MRC sum scores and MIRS grades (ICC=0.69 and 0.71, respectively), indicating good external construct validity. DM1-Activ is a practical, reliable and valid outcome measure that fulfils all clinimetric requirements. Further evaluation of this scale is needed to provide a nomogram for clinical use. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20363134     DOI: 10.1016/j.nmd.2010.03.010

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  13 in total

1.  Assessment of muscular strength and functional capacity in the juvenile and adult myotonic dystrophy type 1 population: a 3-year follow-up study.

Authors:  Marie-Pier Roussel; Marie-Michèle Fiset; Laurie Gauthier; Claudia Lavoie; Émilie McNicoll; Laurie Pouliot; Cynthia Gagnon; Elise Duchesne
Journal:  J Neurol       Date:  2021-04-27       Impact factor: 4.849

2.  Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure.

Authors:  Chad Heatwole; Rita Bode; Nicholas Johnson; Jeanne Dekdebrun; Nuran Dilek; Mark Heatwole; James E Hilbert; Elizabeth Luebbe; William Martens; Michael P Mcdermott; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard Moxley
Journal:  Muscle Nerve       Date:  2014-06       Impact factor: 3.217

3.  The facioscapulohumeral muscular dystrophy Rasch-built overall disability scale (FSHD-RODS).

Authors:  Karlien Mul; Tatiana Hamadeh; Corinne G C Horlings; Rabi Tawil; Jeffrey M Statland; Sabrina Sacconi; Alastair J Corbett; Nicol C Voermans; Catharina G Faber; Baziel G M van Engelen; Ingemar S J Merkies
Journal:  Eur J Neurol       Date:  2021-05-02       Impact factor: 6.089

4.  Modifying the Medical Research Council grading system through Rasch analyses.

Authors:  Els Karla Vanhoutte; Catharina Gerritdina Faber; Sonja Ingrid van Nes; Bart Casper Jacobs; Pieter Antoon van Doorn; Rinske van Koningsveld; David Reid Cornblath; Anneke Jelly van der Kooi; Elisabeth Aviva Cats; Leonard Hendrik van den Berg; Nicolette Claudia Notermans; Willem Lodewijk van der Pol; Mieke Catharina Elisabeth Hermans; Nadine Anna Maria Elisabeth van der Beek; Kenneth Craig Gorson; Marijke Eurelings; Jeroen Engelsman; Hendrik Boot; Ronaldus Jacobus Meijer; Giuseppe Lauria; Alan Tennant; Ingemar Sergio José Merkies
Journal:  Brain       Date:  2011-12-20       Impact factor: 13.501

5.  Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): study protocol for randomised controlled trial.

Authors:  Baziel van Engelen
Journal:  Trials       Date:  2015-05-23       Impact factor: 2.279

6.  Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR).

Authors:  Anna J Roy; Peter Van den Bergh; Philip Van Damme; Kris Doggen; Viviane Van Casteren
Journal:  Acta Neurol Belg       Date:  2014-06-24       Impact factor: 2.396

7.  Reconstructing the Rasch-Built Myotonic Dystrophy Type 1 Activity and Participation Scale.

Authors:  Mieke C E Hermans; Janneke G J Hoeijmakers; Catharina G Faber; Ingemar S J Merkies
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

8.  Functional impairment in patients with myotonic dystrophy type 1 can be assessed by an ataxia rating scale (SARA).

Authors:  Giovanni DiPaolo; Cecilia Jimenez-Moreno; Nikoletta Nikolenko; Antonio Atalaia; Darren G Monckton; Michela Guglieri; Hanns Lochmüller
Journal:  J Neurol       Date:  2017-02-06       Impact factor: 4.849

9.  Analysis of the functional capacity outcome measures for myotonic dystrophy.

Authors:  Aura Cecilia Jimenez-Moreno; Nikoletta Nikolenko; Marie Kierkegaard; Alasdair P Blain; Jane Newman; Charlotte Massey; Dionne Moat; Jas Sodhi; Antonio Atalaia; Grainne S Gorman; Chris Turner; Hanns Lochmüller
Journal:  Ann Clin Transl Neurol       Date:  2019-07-22       Impact factor: 4.511

10.  Swallow-related quality of life and oropharyngeal dysphagia in myotonic dystrophy.

Authors:  Walmari Pilz; Valéria Lima Passos; Rob J Verdonschot; Jolanda Meijers; Nel Roodenburg; Yana Halmans; Catharina G Faber; Bernd Kremer; Laura W J Baijens
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-04-15       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.